This site uses cookies, including third-party cookies, that help us to provide and improve our services.

Privacy Policy
- Global Locations -
Headquarters
Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive, Suite 401, Newark, Delaware - 19713, United States
T: +1-845-579-5705
MEA
Market Access DMCC
1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
Americas
Future Market Insights
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
Europe
Future Market Insights
3rd Floor, 207 Regent Street,
London W1B 3HH
United Kingdom
T: + 44 (0) 20 8123 9659
D: +44 (0) 20 3287 4268
APAC
Future Market Insights
Office No. 401-A, 4th Floor,
VANTAGE 9, S.No. 36/1/1,
Baner, Pune 411045 India

PARP Inhibitors Market

Market Insights on PARP Inhibitors covering sales outlook, demand forecast & up-to-date key trends

PARP Inhibitors by Drug Type (Olaparib, Niraparib, Rucaparib, Talazoparib), Indication (Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer), Distribution Channel (Hospital Pharmacies, Retail Pharmacies,) & Region for 2022-2026

PARP Inhibitors Outlook – 2022-2026

[179 Pages Report] The global Poly Adenosine Diphosphate-Ribose Polymerase (PARP) Inhibitors Market is estimated to top US$ 5.51 Bn by 2022. Surging demand for advanced targeted therapy for the treatment of chronic diseases such as cancer is augmenting the growth in the market.

Attribute

Details

PARP Inhibitors Market Estimated Size in 2022

US$ 5.51 Bn

PARP Inhibitors Market Projected Size in 2026

US$ 8.43 Bn

PARP Inhibitors Market Historical CAGR (2014-2021)

90.4%

PARP Inhibitors Market Value-based CAGR (2022-2026)

11.2%

As per Future Market Insights (FMI), the demand in the PARP inhibitors market is expected to surpass US$ 8.43 Bn, growing at an impressive CAGR of 11.2% during the forecast period 2022-2026.

Among drug type verticals, olaparib is estimated to remain the most sought-after drug in the global market, accounting for more than 62.9% of the PARP inhibitors sales by 2022. FMI states that the PARP inhibitors are estimated to account for over 28.5% of the revenue share in the global cytotoxic toxic drugs market.

Customize this Report

Let us know your requirement to get
100% FREE customization

How The Market Progressed Till June 2022?

Particulars

Details

H1, 2021

14.56%

H1, 2022 Projected

10.84%

H1, 2022 Outlook

9.54%

BPS Change - H1, 2022 (O) – H1, 2022 (P)

(-) 130 ↓

BPS Change – H1, 2022 (O) – H1, 2021

(-) 502 ↓

The variation between the BPS values observed within this market in H1, 2022 - outlook over H1, 2022 projected reflects a decline of 130 units. A steep decline in BPS growth in H1-2022 over H1-2021 by 502 Basis Point Share (BPS) is demonstrated by the PARP inhibitors market.

The market decline observed through the drop in the BPS values is addressed by the reported haematological toxicities induced by the PARP inhibitors, and the adverse effects associated with the therapy. Moreover, PARP inhibitor therapy has been reported to pose a great financial burden on patients, thus lowering its adherence rate, and consequently, the sales adoption.

The global PARP inhibitors market is subject to drug safety guidelines, and therapeutic reimbursements, in accordance to the macro and industrial scale factors.

The key developments in the market include the identification of new target sites for the PARP inhibitor drugs, as well as their potential for application in several disease indications. The market is highly influenced by stringent policies for regulation and licensing of drugs and molecular entities used for clinical purposes.

2014-2021 PARP Inhibitors Market Outlook in Comparison to 2022-2026 Growth Forecast

PARP inhibitors are a group of pharmacological inhibitors of the enzyme, poly ADP ribose polymerase. These inhibitors block PARP enzymes, preventing healthy cells from DNA damage and assist in repairing the damaged part of DNA in cancerous cells.

According to a study by Penn Medicine Organization, use of PARP inhibitors have showcased impressive cancer patient treatment outcome, especially when combined with other therapies such as radiation and chemo.

PARP Inhibitors Market Download Report Brochure

Driven by this, PARP inhibitors has registered a robust surge in demand over the last assessment year, exhibiting growth at a staggering CAGR of 90.4% between 2014 and 2021.

Thus, growing PARP inhibitors usage for increasing cytotoxicity in cancer patients to eliminate cancer cells in BRCA-mutation cancer cell lines and inhibiting DNA damage repair when combined with chemotherapies is propelling the demand in the market. This is expected to assist the global PARP inhibitors market to total US$ 8.43 Bn by the end of 2026.

How is the Rising Burden of Cancer Creating Growth Avenues for the PARP Inhibitors Market?

Prevalence of fatal diseases such as cancer is rapidly increasing worldwide due to growing obesity and increasing smoking and alcohol consumption, resulting in propelling the demand for associated treatments.

According to a report by the World Health Organization (WHO), cancer is a leading cause of death across the world, accounting for approximately 10 million deaths in the year 2020. Out of which nearly 685,000 deaths were caused due to breast cancer.

PARP inhibitors possess the unique ability to improve progression-free survival and repair DNA damage in cells. Attributed to this, these inhibitors are extensively being used for the treatment of various types of cancers such as ovarian and breast cancer. Hence, increasing burden of cancer is estimated to create lucrative sales opportunities for cancer therapeutics such as PARP inhibitors in the coming years.

As per FMI, the sales of PARP inhibitors are estimated to total US$ 5.51 Bn by 2022, accelerating at 11.2% CAGR over the forecast period 2022-2026.

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

How will Increasing Number of Cancer Awareness Campaigns Elevate the PARP Inhibitors Market Growth?

With increasing prevalence and fatalities due to breast, ovarian, prostate, and other cancers, governmental and non-governmental organizations are increasingly undertaking number of public awareness campaigns regarding early cancer diagnosis and treatment.

For instance, the Ministry of Health and Family Welfare has launched a National Programme for Prevention & Control of Cancer, Diabetes, Cardiovascular Diseases & Stroke (NPCDCS) to strengthen treatment infrastructure and spreads awareness regarding early diagnosis of non-communicable diseases such as cancer.

In addition to this, collaborative efforts by market players and research & academic institutes to curb cancer deaths are estimated to spur the sales of PARP inhibitors. Driven by this, the global PARP inhibitors market is expected to expand by 1.52x between 2022 and 2026.

Country-wise Analysis

What are the Factor Favoring U.S. PARP Inhibitors Growth?

“Growing Product Approvals by FDA to Bolster the Sales of Niraparib PARP Inhibitors”

The U.S. is estimated to continue dominating the North America PARP inhibitors during the forecast period 2022-2026.

As the demand for advanced cancer therapeutics such as PARP inhibitors continues to surge, leading regulatory bodies in the country are increasingly focusing on studying and granting approvals for new cancer treatment.

For instance, in 2020, the U.S. Food and Drug Administration (FDA) announced granting approval for new Niraparib PARP inhibitor monotherapy for first-line treatment for ovarian cancer. A multiplicity of such development and new product launches is anticipated to facilitate the sales of PARP inhibitors in the U.S. market. 

Why is the Demand for PARP Inhibitors Surging in the India Market?

“Increasing Cases of Breast Cancer to Fuel the Demand for PARP Inhibitors”

India is forecast to emerge as a highly lucrative market for PARP inhibitors in South Asia between 2022 and 2026.

A significant rise in burden of breast cancer is being witnessed across India, creating strong demand for cancer diagnostics and treatment in the market. According to the Indian Council of Medical Research (ICMR), breast cancer is the most common type of cancer found in Indian women. In 2018, nearly 162,468 new cases and 87,090 fatalities due to breast cancer were reported across India.

As PARP inhibitors are increasingly being used in combination with other breast cancer treatments such as radiation and chemotherapies for repairing DNA damage post-exposure to ultraviolet (UV) radiation, rising prevalence of breast cancer is expected to favor the growth in the India market.

Why is the PARP Inhibitors Market in the U.K. Expanding at Rapid Pace?

“Growing Emphasis on Public Awareness Regarding Cancer to Propel the PARP Inhibitors Demand”

The U.K. is projected to account for a significant share in the Europe PARP inhibitors over the assessment period, reveals FMI.

Increasing government and non-government organizations’ emphasis on spreading public awareness regarding early diagnosis and treatment for cancer is the primary factor bolstering the sales of PARP inhibitors in the U.K. market.

For instance, Public Health England has launched a new campaign ‘Be Clear on Cancer,’ which focuses on improving early cancer diagnostics by spreading public awareness regarding cancer. In addition to this, the presence of favorable medical reimbursement policies in the U.K. is anticipated to bolster the demand for PARP inhibitors in the market.

Become a MarketNgage Insider

An unified Market Research Subscription Platform, built for today’s disparate research needs.

Category-wise Insights

Why are Olaparib PARP Inhibitors Gaining Popularity in the Market?

“Olaparib to Remain the Most Preferred PARP Inhibitors Drug in the Market”

The olaparib segment is expected to register the fastest growth in the global PARP inhibitors market, accounting for more than 62.9% of the revenue share by the end of 2022.

Increasing product approvals and growing adoption of olaparib PARP inhibitors for the treatment of breast cancer, ovarian cancer, and pancreatic cancer is estimated to facilitate growth in the segment. Apart from this, the niraparib segment is estimated to exhibit robust growth, account for nearly 1/3rd of the PARP inhibitors sales through 2022.

Which Indication Segment will Register Robust Growth?

“Growing Adoption in Advanced First line Settings to Accelerate PARP indicator Sales”

On the basis of indication, the prostate cancer segment is anticipated to account for a significant share in the PARP indicator market through 2026, reveals FMI.

The leading factor favoring the growth in the market is growing burden of prostate cancer worldwide. According to the World Cancer Research Fund, prostate cancer is the 2nd most common type of cancer found in men and 4th most commonly occurring cancer overall.

In addition, increasing adoption of olaparib in advanced first-line settings for prostate cancer treatment is expected to spur the sales of PARP indicators in the segment.

Why are the Sales of PARP Inhibitors Rising in Retail Pharmacies Segment?

“Retail Pharmacies to Outrank Other Distribution Channels in the PARP indicator Market”

In terms of distribution channel, the global PARP indicator market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. FMI reveals that the retail pharmacies segment is forecast to account for the dominants share, creating an absolute dollar opportunity of US$ 4 Bn from 2022 to 2026.

Besides this, the online pharmacies segment is forecast to exhibit growth at a rapid CAGR through 2026. Increasing customer inclination towards using online platforms for purchasing medication and other medical accessories is projected to drive the sales of PARP indicators in the segment.

Competitive Landscape

Key companies in the global PARP indicator market are aiming at entering into collaboration, merger, acquisition, partnership and agreements with others players to develop new products for expanding their product portfilio. For instance,

  • In May 2019, Clovis Oncology, Inc., American pharmaceutical company announced entering in a collaboration with two companies - Foundation Medicine Inc. and Bristol-Myers Squibb Company for initiating Phase II studies to evaluate in nivolumab combination with rucaparib in patients with endometrial ovarian cancer.

Scope of the Report

Attribute

Details

Forecast Period

2022-2026

Historical Data Available for

2014-2021

Market Analysis

US$ Bn for Value

Key Regions Covered

North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa

Key Countries Covered

US, Canada, Germany, U.K., France, Italy, Spain, Poland, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Vietnam, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, South Africa

Key Segments Covered

Drug type, Indication, Distribution Channel, and Region

Key Companies Profiled

  • AstraZeneca
  • GlaxoSmithKline
  • Merck Co. & Inc
  • GlaxoSmithKline plc
  • AbbVie Inc
  • Clovis Oncology
  • Medivation
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Repare Therapeutics, Inc.
  • Genentech, Inc.
  • Artios Pharma
  • Repare Therapeutics Inc.
  • Sierra Oncology, Inc.
  • KaryopharmTherapeutics Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Jiangsu Hengrui Medicine Co., Ltd.

Report Coverage

Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives

Customization & Pricing

Available upon Request

PARP Inhibitors Market by Category

By Drug Type:

  • Olaparib
  • Niraparib
  • Rucaparib
  • Talazoparib

By Indication:

  • Ovarian Cancer
  • Breast Cancer
  • Prostate Cancer
  • Pancreatic Cancer

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Europe
  • Latin America
  • South Asia
  • East Asia
  • Oceania
  • Middle East And Africa

Frequently Asked Questions

The PARP inhibitors market is expected to surpass a valuation of US$ 5.51 Bn in 2022.

The global PARP inhibitors market grew at a 90.4% CAGR over the past assessment period 2014-2021.

The PARP inhibitors market is expected to register remarkable growth, expanding at 11.2% CAGR between 2022 and 2026.

North America will emerge as the most lucrative market for PARP inhibitors between 2022 and 2026.

South Asia PARP inhibitors market will hold a significant share over the assessment period 2022-2026.

In terms of drug type, the olaparib segment is expected to account for maximum sales in the global PARP inhibitors market through 2026.

Table of Content

1. Executive Summary

    1.1. Global Market Outlook

    1.2. Demand Side Trends

    1.3. Supply Side Trends

    1.4. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Key Market Trends

    3.1. Key Trends Impacting The Market

4. Key Inclusions

    4.1. Key Regulations

    4.2. Pipeline Analysis

    4.3. Epidemiology for Different Cancer, By Country

5. Global PARP Inhibitors Market Demand (in Value or Size in US$ Mn) Analysis 2015-2021 and Forecast, 2022-2026

    5.1. Historical Market Value (US$ Mn) Analysis, 2015-2021

    5.2. Current and Future Market Value (US$ Mn) Projections, 2022-2026

        5.2.1. Y-o-Y Growth Trend Analysis

        5.2.2. Absolute $ Opportunity Analysis

6. Market Background

    6.1. Macro-Economic Factors

    6.2. Forecast Factors - Relevance & Impact

    6.3. Market Dynamics

        6.3.1. Drivers

        6.3.2. Restraints

        6.3.3. Opportunity Analysis

7. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Drug Type

    7.1. Introduction / Key Findings

    7.2. Historical Market Size (US$ Mn) Analysis By Drug Type, 2015-2021

    7.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Type, 2022-2026

        7.3.1. Niraparib

        7.3.2. Olaparib 

        7.3.3. Rucaparib

        7.3.4. Talazoparib 

    7.4. Market Attractiveness Analysis By Drug Type 

8. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Indication

    8.1. Introduction / Key Findings

    8.2. Historical Market Size (US$ Mn) Analysis By Indication, 2015-2021

    8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Indication, 2021 - 2021

        8.3.1. Ovarian Cancer

        8.3.2. Breast Cancer

        8.3.3. Prostate Cancer

        8.3.4. Pancreatic Cancer

    8.4. Market Attractiveness Analysis By Indication

9. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Distribution Channel

    9.1. Introduction / Key Findings

    9.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2015-2021

    9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2021 - 2021

        9.3.1. Hospital Pharmacies

        9.3.2. Retail Pharmacies

        9.3.3. Online Pharmacies

    9.4.  Market Attractiveness Analysis By Distribution Channel

10. Global PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026, by Region

    10.1. Introduction

    10.2. Historical Market Size (US$ Mn) Analysis By Region, 2015-2021

    10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2021 - 2021

        10.3.1. North America

        10.3.2. Latin America

        10.3.3. Europe

        10.3.4. South Asia

        10.3.5. East Asia

        10.3.6. Oceania

        10.3.7. Middle East and Africa (MEA)

    10.4. Market Attractiveness Analysis By Region

11. North America PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026

    11.1. Introduction

    11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026

        11.3.1.  By Country

            11.3.1.1. U.S.

            11.3.1.2. Canada

        11.3.2. By Drug Type

        11.3.3. By Indication

        11.3.4. By Distribution Channel

    11.4. Market Attractiveness Analysis

    11.5. Key Market Participants - Intensity Mapping

    11.6. Drivers and Restraints - Impact Analysis

12. Latin America PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026

    12.1. Introduction

    12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026

        12.3.1.  By Country

            12.3.1.1. Brazil

            12.3.1.2. Mexico

            12.3.1.3. Argentina

            12.3.1.4. Rest of Latin America

        12.3.2. By Drug Type

        12.3.3. By Indication

        12.3.4. By Distribution Channel

    12.4. Market Attractiveness Analysis

    12.5. Key Market Participants - Intensity Mapping

    12.6. Drivers and Restraints - Impact Analysis

13. Europe PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026

    13.1. Introduction

    13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026

        13.3.1.  By Country

            13.3.1.1. Germany

            13.3.1.2. Italy

            13.3.1.3. France

            13.3.1.4. U.K.

            13.3.1.5. Spain

            13.3.1.6. Rest of Europe

        13.3.2. By Drug Type

        13.3.3. By Indication

        13.3.4. By Distribution Channel

    13.4. Market Attractiveness Analysis

    13.5. Key Market Participants - Intensity Mapping

    13.6. Drivers and Restraints - Impact Analysis

14. South Asia PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026

    14.1. Introduction

    14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026

        14.3.1.  By Country

            14.3.1.1. India

            14.3.1.2. Rest of South Asia

        14.3.2. By Drug Type

        14.3.3. By Indication

        14.3.4. By Distribution Channel

    14.4. Market Attractiveness Analysis

    14.5. Key Market Participants - Intensity Mapping

    14.6. Drivers and Restraints - Impact Analysis

15. East Asia PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026

    15.1. Introduction

    15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026

        15.3.1.  By Country

            15.3.1.1. China

            15.3.1.2. Japan

            15.3.1.3. South Korea

        15.3.2. By Drug Type

        15.3.3. By Indication

        15.3.4. By Distribution Channel

    15.4. Market Attractiveness Analysis

    15.5. Key Market Participants - Intensity Mapping

    15.6. Drivers and Restraints - Impact Analysis

16. Oceania PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026

    16.1. Introduction

    16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    16.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026

        16.3.1.  By Country

            16.3.1.1. Australia

            16.3.1.2. New Zealand

        16.3.2. By Drug Type

        16.3.3. By Indication

        16.3.4. By Distribution Channel

    16.4. Market Attractiveness Analysis

    16.5. Key Market Participants - Intensity Mapping

    16.6. Drivers and Restraints - Impact Analysis

17. Middle East and Africa PARP Inhibitors Market Analysis 2015-2021 and Forecast 2022-2026

    17.1. Introduction

    17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2015-2021

    17.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2022-2026

        17.3.1.  By Country

            17.3.1.1. Turkey

            17.3.1.2. Rest of Middle East and Africa

        17.3.2. By Drug Type

        17.3.3. By Indication

        17.3.4. By Distribution Channel

    17.4. Market Attractiveness Analysis

    17.5. Key Market Participants - Intensity Mapping

    17.6. Drivers and Restraints - Impact Analysis

18. Market Structure Analysis

    18.1. Market Analysis by Tier of Companies (Tissue Diagnostics )

    18.2. Market Concentration

    18.3. Market Share Analysis of Top Players

    18.4. Market Presence Analysis

        18.4.1. By Regional Footprint of Players

        18.4.2. Product Footprint by Players

        18.4.3. Channel Footprint by Players

19. Competition Analysis

    19.1. Competition Dashboard

    19.2. Pricing Analysis by Competition

    19.3. Competition Benchmarking

    19.4. Competition Deep Dive 

        19.4.1. Pfizer Inc.

            19.4.1.1.  Overview

            19.4.1.2. Product Portfolio

            19.4.1.3. Sales Footprint

            19.4.1.4. Analyst commentary

        19.4.2. AstraZeneca

            19.4.2.1. Overview

            19.4.2.2. Product Portfolio

            19.4.2.3. Sales Footprint

            19.4.2.4. Analyst commentary

        19.4.3. Merck & Co. Inc.

            19.4.3.1. Overview

            19.4.3.2. Product Portfolio

            19.4.3.3. Sales Footprint

            19.4.3.4. Analyst commentary

        19.4.4. GlaxoSmithKline Plc. (TESARO INC.)

            19.4.4.1. Overview

            19.4.4.2. Product Portfolio

            19.4.4.3. Sales Footprint

            19.4.4.4. Analyst commentary

        19.4.5. Clovis Oncology

            19.4.5.1. Overview

            19.4.5.2. Product Portfolio

            19.4.5.3. Sales Footprint

            19.4.5.4. Analyst commentary

        19.4.6. BeiGene

            19.4.6.1. Overview

            19.4.6.2. Product Portfolio

            19.4.6.3. Sales Footprint

            19.4.6.4. Analyst commentary

        19.4.7. Jiangsu Hengrui Medicine Co.

            19.4.7.1. Overview

            19.4.7.2. Product Portfolio

            19.4.7.3. Sales Footprint

            19.4.7.4. Analyst commentary

        19.4.8. Oncology Venture AB

            19.4.8.1. Overview

            19.4.8.2. Product Portfolio

            19.4.8.3. Sales Footprint

            19.4.8.4. Analyst commentary

20. Assumptions and Acronyms Used

21. Research Methodology

Customize this Report

Let us know your requirement to get
100% FREE customization

List of Tables

Table 01A: Funding by Research Areas 2021 (US$ Millions)

Table 01B: Funding by Research Areas 2021 (US$ Millions)

Table 02: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Drug Type

Table 03: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Indication

Table 04: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Distribution Channel 

Table 05: Global PARP Inhibitors Market Size (US$ Mn) Analysis 2015–2021 and Opportunity Assessment 2022–2026, By Region

Table 06: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country

Table 07: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type

Table 08: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication

Table 09: North America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel

Table 10: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country

Table 11: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type

Table 12: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication

Table 13: Latin America PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel

Table 14: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country

Table 15: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type

Table 16: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication

Table 17: Europe PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel

Table 18: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country

Table 19: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type

Table 20: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication

Table 21: South Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel

Table 22: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country

Table 23: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type

Table 24: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication

Table 25: East Asia PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel

Table 26: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country

Table 27: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type

Table 28: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication

Table 29: Oceania PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel

Table 30: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Country

Table 31: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Drug Type

Table 32: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Indication

Table 33: MEA PARP Inhibitors Market Size (US$ Mn) Analysis 2015-2021 and Opportunity Assessment 2022-2026, By Distribution Channel

Sabyasachi Ghosh
Principal Consultant
LinkedIn
Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Talk to Analyst

List of Charts

Figure 01: Global PARP Inhibitors Historical Market Size and Y-o-Y, 2015–2021

Figure 02: Global PARP Inhibitors Market Size (US$ Mn) & Y-o-Y Growth (%), 2022–2026

Figure 03: Global PARP Inhibitors Market Absolute $ Opportunity, 2015–2026

Figure 04: Global PARP Inhibitors Market Share Analysis (%) By Drug Type, 2022 & 2026

Figure 05: Global PARP Inhibitors Market Y-o-Y Growth (%) By Drug Type, 2022–2026

Figure 06: Global PARP Inhibitors Market Attractiveness Analysis, By Drug Type

Figure 07: Global PARP Inhibitors Market Share Analysis (%) By Indication, 2022 & 2026

Figure 08: Global PARP Inhibitors Market Y-o-Y Growth (%) By Indication, 2022–2026

Figure 09: Global PARP Inhibitors Market Attractiveness Analysis, By Indication

Figure 10: Global PARP Inhibitors Market Share Analysis (%) By Distribution Channel, 2022 & 2026

Figure 11: Global PARP Inhibitors Market Y-o-Y Growth (%) By Distribution Channel, 2022–2026

Figure 12: Global PARP Inhibitors Market Attractiveness Analysis, By Distribution Channel 

Figure 13: Global PARP Inhibitors Market Share Analysis (%) By Region, 2022 & 2026

Figure 14: Global PARP Inhibitors Market Y-o-Y Growth (%) By Region, 2022–2026

Figure 15: Global PARP Inhibitors Market Attractiveness Analysis, By Region

Figure 16: North America PARP Inhibitors Market Size (US$ Mn), 2015-2021

Figure 17: North America PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026

Figure 18: North America PARP Inhibitors Market Analysis by Country – 2022 & 2026

Figure 19: North America PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026

Figure 20: North America PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026

Figure 21: North America PARP Inhibitors Market Analysis by Drug Type –2022 & 2026

Figure 22: North America PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026

Figure 23: North America PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026

Figure 24: North America PARP Inhibitors Market Analysis by Indication –2022 & 2026

Figure 25: North America PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026

Figure 26: North America PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026

Figure 27: North America PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026

Figure 28: North America PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026

Figure 29: North America PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026

Figure 30: Latin America PARP Inhibitors Market Size (US$ Mn), 2015-2021

Figure 31: Latin America PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026

Figure 32: Latin America PARP Inhibitors Market Analysis by Country – 2022 & 2026

Figure 33: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026

Figure 34: Latin America PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026

Figure 35: Latin America PARP Inhibitors Market Analysis by Drug Type –2022 & 2026

Figure 36: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026

Figure 37: Latin America PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026

Figure 38: Latin America PARP Inhibitors Market Analysis by Indication –2022 & 2026

Figure 39: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026

Figure 40: Latin America PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026

Figure 41: Latin America PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026

Figure 42: Latin America PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026

Figure 43: Latin America PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026

Figure 44: Europe PARP Inhibitors Market Size (US$ Mn), 2015-2021

Figure 45: Europe PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026

Figure 46: Europe PARP Inhibitors Market Analysis by Country – 2022 & 2026

Figure 47: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026

Figure 48: Europe PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026

Figure 49: Europe PARP Inhibitors Market Analysis by Drug Type –2022 & 2026

Figure 50: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026

Figure 51: Europe PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026

Figure 52: Europe PARP Inhibitors Market Analysis by Indication –2022 & 2026

Figure 53: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026

Figure 54: Europe PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026

Figure 55: Europe PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026

Figure 56: Europe PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026

Figure 57: Europe PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026

Figure 58: South Asia PARP Inhibitors Market Size (US$ Mn), 2015-2021

Figure 59: South Asia PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026

Figure 60: South Asia PARP Inhibitors Market Analysis by Country – 2022 & 2026

Figure 61: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026

Figure 62: South Asia PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026

Figure 63: South Asia PARP Inhibitors Market Analysis by Drug Type –2022 & 2026

Figure 64: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026

Figure 65: South Asia PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026

Figure 66: South Asia PARP Inhibitors Market Analysis by Indication –2022 & 2026

Figure 67: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026

Figure 68: South Asia PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026

Figure 69: South Asia PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026

Figure 70: South Asia PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026

Figure 71: South Asia PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026

Figure 72: East Asia PARP Inhibitors Market Size (US$ Mn), 2015-2021

Figure 73: East Asia PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026

Figure 74: East Asia PARP Inhibitors Market Analysis by Country – 2022 & 2026

Figure 75: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026

Figure 76: East Asia PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026

Figure 77: East Asia PARP Inhibitors Market Analysis by Drug Type –2022 & 2026

Figure 78: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026

Figure 79: East Asia PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026

Figure 80: East Asia PARP Inhibitors Market Analysis by Indication –2022 & 2026

Figure 81: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026

Figure 82: East Asia PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026

Figure 83: East Asia PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026

Figure 84: East Asia PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026

Figure 85: East Asia PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026

Figure 86: Oceania PARP Inhibitors Market Size (US$ Mn), 2015-2021

Figure 87: Oceania PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026

Figure 88: Oceania PARP Inhibitors Market Analysis by Country – 2022 & 2026

Figure 89: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026

Figure 90: Oceania PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026

Figure 91: Oceania PARP Inhibitors Market Analysis by Drug Type –2022 & 2026

Figure 92: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026

Figure 93: Oceania PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026

Figure 94: Oceania PARP Inhibitors Market Analysis by Indication –2022 & 2026

Figure 95: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026

Figure 96: Oceania PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026

Figure 97: Oceania PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026

Figure 98: Oceania PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026

Figure 99: Oceania PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026

Figure 100: MEA PARP Inhibitors Market Size (US$ Mn), 2015-2021

Figure 101: MEA PARP Inhibitors Market Size (US$) & Y-o-Y Growth (%), 2022–2026

Figure 102: MEA PARP Inhibitors Market Analysis by Country – 2022 & 2026

Figure 103: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Country, 2022-2026

Figure 104: MEA PARP Inhibitors Market Attractiveness Analysis by Country, 2022-2026

Figure 105: MEA PARP Inhibitors Market Analysis by Drug Type –2022 & 2026

Figure 106: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Drug Type, 2022-2026

Figure 107: MEA PARP Inhibitors Market Attractiveness Analysis by Drug Type, 2022-2026

Figure 108: MEA PARP Inhibitors Market Analysis by Indication –2022 & 2026

Figure 109: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Indication, 2022-2026

Figure 110: MEA PARP Inhibitors Market Attractiveness Analysis by Indication, 2022-2026

Figure 111: MEA PARP Inhibitors Market Analysis by Distribution Channel –2022 & 2026

Figure 112: MEA PARP Inhibitors Market Y-o-Y Growth Projections by Distribution Channel, 2022-2026

Figure 113: MEA PARP Inhibitors Market Attractiveness Analysis by Distribution Channel, 2022-2026

Need specific information?

Request Customization

Explore Healthcare Insights

View Reports

Recommendations

Healthcare

Single Dose Radiotherapy Services Market

Published : March 2021

Healthcare

Cancer Tissue Diagnostics Market

Published : March 2021

Healthcare

Cancer Supportive Care Products Market

Published : July 2020

Healthcare

Cancer Diagnostics Market

Published : March 2021

Google translate

PARP Inhibitors Market